Hydroxyurea or chronic exchange transfusions in patients with sickle cell disease: Role of transcranial doppler ultrasound in stroke prophylaxis

Journal of Pediatric Hematology/Oncology

Volumn 31, Issue 1, 2009, Pages 42-44

  Suliman, Heba ^a   Wali, Yasser ^a   Al Saadoon, Muna ^a   Zechariah, Mathew ^a   William, Ranjan R ^a   Gujjar, Arunodaya ^a   Pathare, Anil ^a  

^a SULTAN QABOOS UNIVERSITY HOSPITAL   (Oman)

Author keywords

Doppler; SCD; Sickle; TCD; Transcranial; Ultrasound

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; HYDROXYUREA; MANNITOL; ANTISICKLING AGENT;

ANAMNESIS; ARTICLE; BLOOD CELL COUNT; BLOOD FLOW VELOCITY; BRAIN BLOOD FLOW; BRAIN BLOOD VESSEL; CASE REPORT; CEREBRAL ARTERY DISEASE; CEREBROVASCULAR ACCIDENT; CHILD; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DOPPLER ECHOGRAPHY; DRUG DOSE INCREASE; DYSARTHRIA; EXCHANGE BLOOD TRANSFUSION; FACIAL NERVE PARALYSIS; FEMALE; HEMIPARESIS; HUMAN; PHYSIOTHERAPY; POSTERIOR CEREBRAL ARTERY; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; SICKLE CELL ANEMIA; VASCULAR DISEASE; VERTEBRAL ARTERY; BRAIN ARTERY; BRAIN CIRCULATION; ECHOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; STROKE;

ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; BLOOD FLOW VELOCITY; CEREBRAL ARTERIES; CEREBROVASCULAR CIRCULATION; CHILD, PRESCHOOL; EXCHANGE TRANSFUSION, WHOLE BLOOD; FEMALE; HUMANS; HYDROXYUREA; MAGNETIC RESONANCE IMAGING; STROKE; ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL;

EID: 59449095514     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e318190d707     Document Type: Article

References (12)

1. Kinney TR, Sleeper LA, Wang WC, et al. Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. The Cooperative Study of Sickle Cell Disease. Pediatrics. 1999;103:640-645.
2. Balkan B, Char G, Morris JS, et al. Stroke in a cohort of patients with homozygous Sickle Cell Disease. Paediatrics. 1992;120:360-366.
3. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease rates and risk factors. Blood. 1998;91:288-294.
4. Jones A, Granger S, Brambilla D, et al. Can peak systolic velocities be used for prediction of stroke in sickle cell anemia? Pediatr Radiol. 2005;35:66-72.
5. Adams RJ, McKie VC, Hsu L, et al. Prevention of first stroke by transfusion in children with sickle cell anemia and abnormal results on Transcranial Doppler Ultrasonography. NEJM. 1998;339:5-11.
6. Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase 1/2 trial. Blood. 1999;94: 1550-1554.
7. Ware RE, Eggleston B, Redding-Lallinger R, et al. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood. 2002;99:10-14.
8. Bradai M, Abad MT, Pissard S, et al. Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. Blood. 2003;102:1529-1530.
9. Mehta SH, Adams RJ. Treatment and prevention of stroke in children with sickle cell disease. Curr Treat Options Neurol. 2006;8:503-512.
10. Kratovil T, Bulas D, Driscoll MC, et al. Hydroxyurea therapy lowers TCD velocities in children with sickle cell disease. Pediatric Blood Cancer. 2006;47:894-900.
11. Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl Med. 1997;337:762-769.
12. Gulbis B, Haberman D, Dufour D, et al. Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience. Blood. 2005;105: 2685-2690.